Jasper A. J. Smits

Jasper A. J. Smits

Auto-generated profile, based on publicly available information

Jasper A. J. Smits

The University of Texas at Austin

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2008 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
PDF file
SHStefan G. Hofmann
Stefan G. Hofmann
JSJasper A. J. Smits
Jasper A. J. Smits
Cognitive-behavioral therapy (CBT) is frequently used for various adult anxiety disorders, but there has been no systematic review of the efficacy of CBT in randomized placebo-controlled trials. The present study meta-analytically reviewed the efficacy of CBT versus placebo for adult anxiety disorders. We conducted a computerized search for treatment outcome studies of anxiety disorders from the first available date to March 1, 2007. We searched MEDLINE, PsycINFO, PubMed, Scopus, the Institute of Scientific Information, and Dissertation Abstracts International for the following terms: random*, cognitive behavior*therap*, cognitive therap*, behavior*therap*, GAD, generalized anxiety disorder, OCD, obsessive compulsive disorder, social phobia, social anxiety disorder, specific phobia, simple phobia, PTSD, post-traumatic stress disorder, and acute stress disorder. Furthermore, we examined reference lists from identified articles and asked international experts to identify eligible studies. We included studies that randomly assigned adult patients between ages 18 and 65 years meeting DSM-III-R or DSM-IV criteria for an anxiety disorder to either CBT or placebo. Of 1165 studies that were initially identified, 27 met all inclusion criteria. The 2 authors independently identified the eligible studies and selected for each study the continuous measures of anxiety severity. Dichotomous measures reflecting treatment response and continuous measures of depression severity were also collected. Data were extracted separately for completer (25 studies for continuous measures and 21 studies for response rates) and intent-to-treat (ITT) analyses (6 studies for continuous measures and 8 studies for response rates). There were no significant differences in attrition rates between CBT and placebo. Random-effects models of completer samples yielded a pooled effect size (Hedges' g) of 0.73 (95% CI = 0.88 to 1.65) for continuous anxiety severity measures and 0.45 (95% CI = 0.25 to 0.65) for depressive symptom severity measures. The pooled odds ratio for completer treatment response rates was 4.06 (95% CI = 2.78 to 5.92). The strongest effect sizes were observed in obsessive-compulsive disorder and acute stress disorder, and the weakest effect size was found in panic disorder. The advantage of CBT over placebo did not depend on placebo modality, number of sessions, or study year. Our review of randomized placebo-controlled trials indicates that CBT is efficacious for adult anxiety disorders. There is, however, considerable room for improvement. Also, more studies need to include ITT analyses in the future.

16 February 2018 in Depression and Anxiety
Verified
Journal Article
Closed access
PDF file
JCJoseph K. Carpenter
Joseph K. Carpenter
LALeigh A. Andrews
Leigh A. Andrews
SWSara M. Witcraft
Sara M. Witcraft
MPMark B. Powers
Mark B. Powers
JSJasper A. J. Smits
Jasper A. J. Smits
SHStefan G. Hofmann
Stefan G. Hofmann

24 December 2014 in Psychotherapy and Psychosomatics
Verified
Journal Article
Closed access
PDF file
JAJacqueline G.L. A-Tjak
Jacqueline G.L. A-Tjak
MDMichelle L. Davis
Michelle L. Davis
NMNexhmedin Morina
Nexhmedin Morina
MPMark B. Powers
Mark B. Powers
JSJasper A.J. Smits
Jasper A.J. Smits
PEPaul M.G. Emmelkamp
Paul M.G. Emmelkamp
Background: The current study presents the results of a meta-analysis of 39 randomized controlled trials on the efficacy of acceptance and commitment therapy (ACT), including 1,821 patients with mental disorders or somatic health problems. Methods: We searched PsycINFO, MEDLINE and the Cochrane Central Register of Controlled Trials. Information provided by the ACBS (Association of Contextual Behavioral Science) community was also included. Statistical calculations were conducted using Comprehensive Meta-Analysis software. Study quality was rated using a methodology rating form. Results: ACT outperformed control conditions (Hedges' g = 0.57) at posttreatment and follow-up assessments in completer and intent-to-treat analyses for primary outcomes. ACT was superior to waitlist (Hedges' g = 0.82), to psychological placebo (Hedges' g = 0.51) and to treatment as usual (TAU) (we defined TAU as the standard treatment as usual; Hedges' g = 0.64). ACT was also superior on secondary outcomes (Hedges' g = 0.30), life satisfaction/quality measures (Hedges' g = 0.37) and process measures (Hedges' g = 0. 56) compared to control conditions. The comparison between ACT and established treatments (cognitive behavioral therapy) did not reveal any significant differences between these treatments (p = 0.140). Conclusions: Our findings indicate that ACT is more effective than treatment as usual or placebo and that ACT may be as effective in treating anxiety disorders, depression, addiction, and somatic health problems as established psychological interventions. More research that focuses on quality of life and processes of change is needed to understand the added value of ACT and its transdiagnostic nature.

1 January 2013 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
BOBunmi O. Olatunji
Bunmi O. Olatunji
MDMichelle L. Davis
Michelle L. Davis
MPMark B. Powers
Mark B. Powers
JSJasper A.J. Smits
Jasper A.J. Smits

1 March 2006 in Archives of General Psychiatry
Verified
Journal Article
Open access
PDF file
SHStefan G. Hofmann
Stefan G. Hofmann
AMAlicia E. Meuret
Alicia E. Meuret
JSJasper A. J. Smits
Jasper A. J. Smits
NSNaomi M. Simon
Naomi M. Simon
MPMark H. Pollack
Mark H. Pollack
MOMichael W. Otto
Michael W. Otto
Social anxiety disorder (SAD) is a common psychiatric disorder with a lifetime prevalence of 13.3%,1 making it the third most common psychiatric condition in the United States behind major depression and alcohol abuse. If untreated, the disorder typically follows a chronic, unremitting course leading to substantial impairments in vocational and social functioning.2-8 Of all social situations, public speaking is the most prevalent fear among individuals with SAD as well as in the general population.7,9,10

1 January 2006 in Clinical Psychology: Science and Practice
Verified
Journal Article
Closed access
PDF file
GSGeorgia Stathopoulou
Georgia Stathopoulou
MPMark B. Powers
Mark B. Powers
ABAngela C. Berry
Angela C. Berry
JSJasper A. J. Smits
Jasper A. J. Smits
MOMichael W. Otto
Michael W. Otto